Abstract
Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy are attributed to FIV-specific T-cell immunity. Findings from these studies are being used to define the prophylactic epitopes needed for an HIV-1 vaccine for humans.
Keywords: FIV, vaccine, AIDS, animal model
Current HIV Research
Title: Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines
Volume: 8 Issue: 1
Author(s): Janet K. Yamamoto, Missa P. Sanou, Jeffrey R. Abbott and James K. Coleman
Affiliation:
Keywords: FIV, vaccine, AIDS, animal model
Abstract: Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy are attributed to FIV-specific T-cell immunity. Findings from these studies are being used to define the prophylactic epitopes needed for an HIV-1 vaccine for humans.
Export Options
About this article
Cite this article as:
Yamamoto K. Janet, Sanou P. Missa, Abbott R. Jeffrey and Coleman K. James, Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines, Current HIV Research 2010; 8 (1) . https://dx.doi.org/10.2174/157016210790416361
DOI https://dx.doi.org/10.2174/157016210790416361 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress on Antifungal Drug Development
Current Pharmaceutical Biotechnology Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry Alzheimers Disease: SPECT and PET Tracers for Beta-Amyloid Imaging
Current Alzheimer Research Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy Antimicrobial Development in the Era of Emerging Resistance
Mini-Reviews in Medicinal Chemistry Natural Compounds Therapeutic Features in Brain Disorders by Experimental, Bioinformatics and Cheminformatics Methods
Current Medicinal Chemistry Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimers Disease: A Review of Recent Clinical Studies
Current Alzheimer Research The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Knowledge, Attitude and Practice (KAP) Survey Concerning Antimicrobial Use among Australian Hajj Pilgrims
Infectious Disorders - Drug Targets The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design A Review of Nanocarrier-Based CNS Delivery Systems
Current Drug Delivery Structural Vaccinology: A Three-dimensional View for Vaccine Development
Current Topics in Medicinal Chemistry Comparative Time-Kill Study of Doxycycline, Tigecycline, Cefazolin and Vancomycin Against Several Clones of Staphylococcus aureus
Current Clinical Pharmacology The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Recent Developments in Synthetic Oligosaccharide-Based Bacterial Vaccines
Current Topics in Medicinal Chemistry